Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: A preliminary report

Journal of Pediatric Gastroenterology and Nutrition

Volumn 35, Issue 3, 2002, Pages 391-398

  Rumbo, Carolina ^a   Emerick, Karan M ^b   Emre, Sukru ^a   Shneider, Benjamin L ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; METHYLMERCAPTOPURINE; STEROID; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; HYPERSPLENISM; LIVER CIRRHOSIS; LIVER TOXICITY; MALE; MEASUREMENT; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; STEROIDS; THIOGUANINE;

EID: 0036736440     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200209000-00032     Document Type: Article

References (15)

1. Maggiore G, Bernard O, Homberg LC. Liver disease associated with anti-liver-kidney microsome antibody in children. J Pediatr 1986;108:399-404.
2. nd ed. Philadelphia: Lippincott Williams Wilkins; 2001:429-41.
3. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
4. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
5. Cuffari C, Hunt S, Bayless T. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
6. Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001;36:71-6.
7. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122:904-15.
8. Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology 1993;18:998-1005.
9. Johnson PJ, Mc Farlane IG, Williams R. Azathioprine for longmaintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-63.
10. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6.
11. Ferroni MA, Marchi G, Sansone E, et al. Variability in the rate of 6-mercaptopurine methylation in the erythrocytes, liver and kidney in an Italian population. Eur J Clin Pharmacol 1996;51:23-9.
12. Pacifici GM, Romiti P, Giuliani L, et al. Thiopurine methyltransferase in humans; development and tissue distribution. Dev Pharmacol Ther 1991;17:16-23.
13. Szumlanski CL, Honchel R, Scott M, et al. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992;2:148-59.
14. Lau RC, Matsui D, Greenberg M, et al. Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. Med Pediatr Oncol 1998;30:85-90.
15. Lurie S, Shemesh E, Sheiner PA, et al. Non-adherence in pediatric liver transplant recipients - an assessment of risk factors and natural history. Pediatr Transplant 2000;4:200-6.